Drug-Induced Liver Injury


Idiosyncratic liver injury associated with drugs (ILIAD)

Enrollment status: OPEN

The goal of the ILIAD protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin®), amoxicillin/clavulanate (Augmentin®), minocycline, nitrofurantoin, trimethroprim/sulfamethoxazole (Bactrim®), or valproic acid (Depakote®), after January 1, 1994. This study is funded by the NIH/NIDDK.

Study design

Contacts for referrals or questions: see below


A multi-center, longitudinal study of drug-induced and complementary and alternative medication—induced liver injury

Enrollment Status: OPEN

The goal of this multicenter NIH study is to prospectively identify bona fide cases of liver injury due to drugs and complementary and alternative medications (CAM) within 6 months of onset. Clinical data, blood, DNA, and urine will be collected from affected patients and matched controls for mechanistic and genetic studies.

Study Design

Costs


Contacts for referrals or questions:

Principal Investigator: Robert Fontana, MD rfontana@med.umich.edu


For more information on drug-induced liver injury, see the following web sites:

Drug-Induced Liver Injury Network: http://dilin.dcri.duke.edu/index.html

NIH funds network to study drug-induced liver injury: http://www.nih.gov/news/pr/nov2004/niddk-19.htm

NIDDK LiverTox web site: http://www.livertox.nih.gov/